Skip to main content
SpringerLink
Log in

Co-expression of galectin-3 and CRIP-1 in endometrial cancer: prognostic value and patient survival

Medical Oncology Aims and scope Submit manuscript

Abstract

Endometrial cancer is the sixth most common cancer in women. Galectin-3 (GAL-3) and CRIP-1 are multifunctional proteins which seem to be involved in many neoplasias. This study aims to point out correlations between clinicopathological findings and endometrial cancer patient survival to GAL-3 and CRIP-1 expression in order to enfold their diagnostic/prognostic potential. Tissues from 46 patients diagnosed with endometrial cancer were studied by immunohistochemistry, using monoclonal antibodies for GAL-3 and CRIP-1, and expression levels were correlated with clinicopathological findings and survival. Analysis was performed at single protein level or as co-expression. High expression of GAL-3 and CRIP-1 was independently associated with tumor depth and histological grade, respectively. Also, there was a significant correlation between high co-expression of the two proteins and the histological grade (aOR 2.66), the tumor depth (aOR 0.32) and the histological type (aOR 1.32), but not with the patients’ age. Moreover, high expression of both proteins was observed in patients with shorter survival times. Interestingly, the co-expression of the two proteins exhibited some degree of monotony (Spearman’s ρ = 0.768), indicating a common molecular pathway. This study provides evidence for a prognostic clinical potential of the combined study of GAL-3 and CRIP-1 in endometrial cancer. These factors are poorly studied in endometrium, and their role in the carcinogenetic process and on effective therapy awaits further elucidation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Yeramian A, Moreno-Bueno G, Dolcet X, et al. Endometrial carcinoma: molecular alterations involved in tumor development and progression. Oncogene. 2013;32(4):403–13.

    Article  CAS  PubMed  Google Scholar 

  2. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2003. CA Cancer J Clin. 2003;53(1):27–43.

    Article  PubMed  Google Scholar 

  3. Saso S, Chatterjee J, Georgiou E, Ditri AM, Smith JR, Ghaem-Maghami S. Endometrial cancer. BMJ. 2011;343:d3954.

    Article  PubMed  Google Scholar 

  4. Di Cristofano A, Ellenson LH. Endometrial carcinoma. Annu Rev Pathol. 2007;2:57–85.

    Article  PubMed  Google Scholar 

  5. Lambropoulou M, Alexiadis G, Limberis V, Nikolettos N, Tripsianis G. Clinicopathologic and prognostic significance of cyclooxygenase-2 expression in endometrial carcinoma. Histol Histopathol. 2005;20(3):753–9.

    CAS  PubMed  Google Scholar 

  6. Lambropoulou M, Stefanou D, Alexiadis G, et al. Cytoplasmic expression of c-erb-B2 in endometrial carcinomas. Onkologie. 2007;30(10):495–500.

    Article  CAS  PubMed  Google Scholar 

  7. Lambropoulou M, Papadopoulos N, Tripsianis G, et al. Co-expression of survivin, c-erbB2, and cyclooxygenase-2 (COX-2) prognostic value and survival of endometrial cancer patients. J Cancer Res Clin Oncol. 2010;136:427–35.

    Article  CAS  PubMed  Google Scholar 

  8. Balan V, Nangia-Makker P, Raz A. Galectins as cancer biomarkers. Cancers (Basel). 2010;2(2):592–610.

    Article  CAS  Google Scholar 

  9. Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer. 2005;5:29–41.

    Article  CAS  PubMed  Google Scholar 

  10. Dumic J, Dabelic S, Flögel M. Galectin-3: an open-ended story. Biochim Biophys Acta. 2006;1760:616–35.

    Article  CAS  PubMed  Google Scholar 

  11. Davidson PJ, Davis MJ, Patterson RJ, Ripoche MA, Poirier F, Wang JL. Shuttling of galectin-3 between the nucleus and cytoplasm. Glycobiology. 2002;12:329–37.

    Article  CAS  PubMed  Google Scholar 

  12. Yu F, Finley RL Jr, Raz A, Kim HR. Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J Biol Chem. 2002;277(18):15819–27.

    Article  CAS  PubMed  Google Scholar 

  13. Mori Y, Akita K, Yashiro M, et al. Binding of galectin-3, a β-galactoside-binding lectin, to MUC1 protein enhances phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) and Akt, promoting tumor cell malignancy. J Biol Chem. 2015;290(43):26125–40.

    Article  CAS  PubMed  Google Scholar 

  14. Califice S, Castronovo V, Van Den Brüle F. Galectin-3 and cancer. Int J Oncol. 2004;25:983–92.

    CAS  PubMed  Google Scholar 

  15. Ochieng J, Fridman R, Nangia-Makker P, et al. Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9. Biochemistry. 1994;33(47):14109–14.

    Article  CAS  PubMed  Google Scholar 

  16. Saussez S, Lorfevre F, Lequeux T, et al. The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy. Oral Oncol. 2008;44(1):86–93.

    Article  CAS  PubMed  Google Scholar 

  17. Cousins RJ, Lanningham-Foster L. Regulation of cysteine-rich intestinal protein, a zinc finger protein, by mediators of the immune response. J Infect Dis. 2000;182(Suppl 1):S81–4.

    Article  CAS  PubMed  Google Scholar 

  18. Lanningham-Foster L, Green CL, Langkamp-Henken B, et al. Overexpression of CRIP in transgenic mice alters cytokine patterns and the immune response. Am J Physiol Endocrinol Metab. 2002;282:E1197–203.

    Article  CAS  PubMed  Google Scholar 

  19. Ma XJ, Salunga R, Tuggle JT, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA. 2003;100(10):5974–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Chen Y, Miller C, Mosher R, et al. Identification of cervical cancer markers by cDNA and tissue microarrays. Cancer Res. 2003;63:1927–35.

    CAS  PubMed  Google Scholar 

  21. Wang Q, Williamson M, Bott S, et al. Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer. Oncogene. 2007;26(45):6560–5.

    Article  CAS  PubMed  Google Scholar 

  22. Terris B, Blaveri E, Crnogorac-Jurcevic T, et al. Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am J Pathol. 2002;160(5):1745–54.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Yamashita K, Upadhyay S, Osada M, et al. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell. 2002;2(6):485–95.

    Article  CAS  PubMed  Google Scholar 

  24. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2008. (ISBN 3-900051-07-0, http://www.R-project.org).

  25. Ruvolo PP. Galectin 3 as a guardian of the tumor microenvironment. Biochim Biophys Acta. 2015. doi:10.1016/j.bbamcr.2015.08.008.

    Google Scholar 

  26. Gendy HE, Madkour B, Abdelaty S, et al. Diagnostic and prognostic significance of serum and tissue galectin 3 expression in patients with carcinoma of the bladder. Curr Urol. 2014;7(4):185–90.

    Article  PubMed Central  PubMed  Google Scholar 

  27. Zeinali M, Adelinik A, Papian S, Khorramdelazad H, Abedinzadeh M. Role of galectin-3 in the pathogenesis of bladder transitional cell carcinoma. Hum Immunol. 2015;76(10):770–4.

    Article  CAS  PubMed  Google Scholar 

  28. Ludyga N, Englert S, Pflieger K, et al. The impact of cysteine-rich intestinal protein 1 (CRIP1) in human breast cancer. Mol Cancer. 2013;12:28.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Balluff B, Rauser S, Meding S, et al. MALDI imaging identifies prognostic seven-protein signature of novel tissue markers in intestinal-type gastric cancer. Am J Pathol. 2011;179(6):2720–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Funding

This study did not receive any specific grant; thus, it was not funded.

Author information

Authors and Affiliations

  1. Laboratories of Histology-Embryology, School of Medicine, Democritus University of Thrace, Dragana, 68 100, Alexandroupolis, Greece

    Maria Lambropoulou, Theodora-Eleftheria Deftereou, Sryridon Kynigopoulos, Anargyros Patsias, Christina Nikolaidou & Nikolaos Papadopoulos

  2. Laboratories of Biochemistry, School of Medicine, Democritus University of Thrace, 68 100, Alexandroupolis, Greece

    Constantinos Anagnostopoulos

  3. Private Radiodiagnostic Center of Alexandroupolis, Theagenio Anticancer Hospital, Thessaloniki, Greece

    Georgios Alexiadis

  4. Laboratories of Medical Physics, School of Medicine, Democritus University of Thrace, 68 100, Alexandroupolis, Greece

    Athanasia Kotini

  5. Laboratories of Department of Surgery, School of Medicine, Democritus University of Thrace, 68 100, Alexandroupolis, Greece

    Alexandra Tsaroucha

  6. Pathology Laboratory, Theagenio Anticancer Hospital, Thessaloniki, Greece

    Anastasia Kiziridou

  7. Laboratories of Pharmacology, School of Medicine, Democritus University of Thrace, 68 100, Alexandroupolis, Greece

    Ekaterini Chatzaki

Authors
  1. Maria Lambropoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Theodora-Eleftheria Deftereou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sryridon Kynigopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anargyros Patsias
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Constantinos Anagnostopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Georgios Alexiadis
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Athanasia Kotini
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Alexandra Tsaroucha
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Christina Nikolaidou
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Anastasia Kiziridou
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Nikolaos Papadopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Ekaterini Chatzaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria Lambropoulou.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The study was in accordance with the ethical standards of our institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lambropoulou, M., Deftereou, TE., Kynigopoulos, S. et al. Co-expression of galectin-3 and CRIP-1 in endometrial cancer: prognostic value and patient survival. Med Oncol 33, 8 (2016). https://doi.org/10.1007/s12032-015-0723-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-015-0723-7

Keywords

search

Navigation